PRESS RELEASE: CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

Nov 2, 2009 1 related

First evaluation of CureVac's RNActive® vaccine technology in humans * German authorities approve CV9103 for Phase IIa trial Tuebingen (Germany), November 2, 2009. CureVac GmbH, the mRNA vaccine company, today announced that... [read full story]

Add Comment

There are also 1 related articles

View all news articles about*:

*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

Send to a friend | Bookmark with

NewstinMap

Click to Open NewstinMap —

Visual Navigation

My Newstin

Context

Male Health
Ambulatory Health Care
Cancer by Body Location
Cancer Therapy
Scientific Discoveries
Health Care
Immunotherapy
Cancers
Pharmaceuticals
Vaccines
Prostate Cancer
Medicines & Remedies
Lung Cancer
Medical Research

Germany

Intelligent Data Fusion

About Us

Visit our corporate homepage to learn more about our company and products.

PRESS RELEASE: CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

View other selected articles:

Man, Machine, and in Between

Hepatic Lipid Composition and Stearoyl-Coenzyme A Desaturase 1 mRNA Expression Can Be Estimated...

Single-celled life does a lot with very little

Research and Markets: Medical Ultrasound Equipment - a Global Market Perspective

International Editions